27446916|t|Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice
27446916|a|Prostate cancer (PCa) is the most common malignancy and the second most common cause of cancer death in Western men. Despite its prevalence, PCa has proven very difficult to propagate in vitro. PCa represents a complex organ-like multicellular structure maintained by the dynamic interaction of tumoral cells with parenchymal stroma, endothelial and immune cells, and components of the extracellular matrix (ECM). The lack of PCa models that recapitulate this intricate system has hampered progress toward understanding disease progression and lackluster therapeutic responses. Tissue slices, monolayer cultures and genetically engineered mouse models (GEMM) fail to mimic the complexities of the PCa microenvironment or reproduce the diverse mechanisms of therapy resistance. Moreover, patient derived xenografts (PDXs) are expensive, time consuming, difficult to establish for prostate cancer, lack immune cell-tumor regulation, and often tumors undergo selective engraftments. Here, we describe an interdisciplinary approach using primary PCa and tumor initiating cells (TICs), three-dimensional (3D) tissue engineering, genetic and morphometric profiling, and humanized mice to generate patient - derived organoids for examining personalized therapeutic responses in vitro and in mice co-engrafted with a human immune system (HIS), employing adaptive T-cell- and chimeric antigen receptor- (CAR) immunotherapy. The development of patient specific therapies targeting the vulnerabilities of cancer, when combined with antiproliferative and immunotherapy approaches could help to achieve the full transformative power of cancer precision medicine.
27446916	0	32	Personalized Medicine Approaches	T058	UMLS:C2718059
27446916	36	51	Prostate Cancer	T038	UMLS:C0600139
27446916	78	80	3D	T082	UMLS:C0450363
27446916	81	90	Organoids	T017	UMLS:C0029250
27446916	95	109	Humanized Mice	T204	UMLS:C0025929
27446916	110	125	Prostate cancer	T038	UMLS:C0600139
27446916	127	130	PCa	T038	UMLS:C0600139
27446916	151	161	malignancy	T038	UMLS:C4282132
27446916	214	221	Western	T082	UMLS:C1705493
27446916	222	225	men	T098	UMLS:C0025266
27446916	251	254	PCa	T038	UMLS:C0600139
27446916	304	307	PCa	T038	UMLS:C0600139
27446916	329	339	organ-like	T017	UMLS:C0178784
27446916	340	363	multicellular structure	T082	UMLS:C0678594
27446916	405	418	tumoral cells	T017	UMLS:C0597032
27446916	424	442	parenchymal stroma	T017	UMLS:C0682552
27446916	444	455	endothelial	T017	UMLS:C0225336
27446916	460	472	immune cells	T017	UMLS:C0312740
27446916	478	488	components	T017	UMLS:C0243092
27446916	496	516	extracellular matrix	T017	UMLS:C0015350
27446916	518	521	ECM	T017	UMLS:C0015350
27446916	536	539	PCa	T038	UMLS:C0600139
27446916	540	546	models	T038	UMLS:C1516211
27446916	616	629	understanding	T038	UMLS:C0162340
27446916	630	649	disease progression	T038	UMLS:C0242656
27446916	665	686	therapeutic responses	T201	UMLS:C0521982
27446916	688	701	Tissue slices	T062	UMLS:C1519528
27446916	703	721	monolayer cultures	T058	UMLS:C1510803
27446916	726	761	genetically engineered mouse models	T038	UMLS:C1522222
27446916	763	767	GEMM	T038	UMLS:C1522222
27446916	807	810	PCa	T038	UMLS:C0600139
27446916	867	874	therapy	T058	UMLS:C0087111
27446916	897	923	patient derived xenografts	T038	UMLS:C4050317
27446916	925	929	PDXs	T038	UMLS:C4050317
27446916	989	1004	prostate cancer	T038	UMLS:C0600139
27446916	1011	1039	immune cell-tumor regulation	T038	UMLS:C1819849
27446916	1051	1057	tumors	T038	UMLS:C0027651
27446916	1076	1088	engraftments	T038	UMLS:C0301944
27446916	1152	1155	PCa	T038	UMLS:C0600139
27446916	1160	1182	tumor initiating cells	T017	UMLS:C1956421
27446916	1184	1188	TICs	T017	UMLS:C1956421
27446916	1191	1208	three-dimensional	T082	UMLS:C0450363
27446916	1210	1212	3D	T082	UMLS:C0450363
27446916	1214	1232	tissue engineering	T058	UMLS:C0596171
27446916	1234	1241	genetic	T058	UMLS:C2986505
27446916	1246	1268	morphometric profiling	T058	UMLS:C0200760
27446916	1274	1288	humanized mice	T204	UMLS:C0025929
27446916	1319	1328	organoids	T017	UMLS:C0029250
27446916	1356	1377	therapeutic responses	T201	UMLS:C0521982
27446916	1394	1398	mice	T204	UMLS:C0025929
27446916	1419	1438	human immune system	T022	UMLS:C0020962
27446916	1440	1443	HIS	T022	UMLS:C0020962
27446916	1465	1472	T-cell-	T017	UMLS:C0039194
27446916	1477	1503	chimeric antigen receptor-	T103	UMLS:C4039583
27446916	1505	1508	CAR	T103	UMLS:C4039583
27446916	1510	1523	immunotherapy	T058	UMLS:C0021083
27446916	1561	1570	therapies	T058	UMLS:C0087111
27446916	1604	1610	cancer	T038	UMLS:C0600139
27446916	1631	1648	antiproliferative	T058	UMLS:C0087111
27446916	1653	1666	immunotherapy	T058	UMLS:C0021083
27446916	1667	1677	approaches	T058	UMLS:C0087111
27446916	1733	1739	cancer	T038	UMLS:C0600139
27446916	1740	1758	precision medicine	T058	UMLS:C2718059